Published on
The Food and Drug Administration (FDA) has approved a continuous glucose and ketone monitoring system, which it says is the first wearable device that monitors both levels simultaneously with a single sensor. The system measures glucose and ketones in interstitial fluid every minute for up to 10 days and transmits the information to the patient’s smartphone. Patients arriving in urgent care will be able to present not just current ketone readings but the direction and trajectory of their ketones with the data gathered in their app. According to FDA, the device can send automatic alerts if ketone levels reach a specified threshold, which may help patients and clinicians recognize rising ketones that may warn of possible diabetic ketoacidosis.
Information for consideration: FDA specifically states that ketone information should be interpreted in conjunction with glucose readings and the patient’s symptoms. The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System is indicated for people with diabetes aged 2 years and older with a prescription, and it is expected to launch later this year, according to manufacturer Abbott Diabetes Care.